Skip to main content
. 2020 May 6;13:3823–3837. doi: 10.2147/OTT.S240721

Figure 3.

Figure 3

The combination of chidamide and bortezomib synergistically enhanced MGC-803 and BGC-823 cell apoptosis. The MGC-803 and BGC-823 cell lines were treated with chidamide (30 µM for MGC-803 or 20 µM for BGC-823), bortezomib (15 nM), chidamide (120 µM for MGC-803 or 80 µM for BGC-823), or chidamide (30 µM for MGC-803 or 20 µM for BGC-823) in combination with bortezomib (15 nM) for 48 hours. (A and B) Representative images of the expression of the apoptosis-related proteins cleaved caspase-3, P53, and Bcl-2. (C and D) Flow cytometry of the number of cells in the apoptotic state after the different treatments, and their statistics. (One-way ANOVA with Bonferroni’s post hoc test was applied to compare the indicated groups. ***P<0.001, compared with the negative control, chidamide-, or bortezomib-alone groups). The experiment was repeated at least three times. Negative control: DMSO.